International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (4) ; 10.12208/j.ijcr.20250220 .
总浏览量: 79
山东省菏泽市郓城县李集镇卫生院苏阁分院 山东菏泽
*通讯作者： 李爱荣,单位：山东省菏泽市郓城县李集镇卫生院苏阁分院 山东菏泽；
目的 基于抗衰效应探究乙酰半胱氨酸联合布地奈德雾化治疗老年慢阻肺患者的效果。方法 参与本次研究患者的数量60例，研究的起始时间为2024年1月份，截止时间为2024年12月份，将其分成两组，对照组与实验组，每组患者的数量为30例，对照组为布地奈德雾化吸入；实验组在对照组基础上提供乙酰半胱氨酸治疗，分析两组患者的血氧指标、炎症因子、不良反应、生活质量。结果 两组患者提供不同的干预措施后，实验组患者的血氧指标优于对照组，p<0.05，评估患者的炎症因子水平，实验组患者的炎症因子水平显佳，p<0.05，对比患者的不良反应，实验组患者不良反应低于对照组，p<0.05，对比患者生活质量，实验组优于对照组，p<0.05。结论 对老年慢阻肺患者提供乙酰半胱氨酸联合布地奈德雾化治疗，可以改善患者的血氧指标，稳定患者的炎症因子水平，降低不良反应的产生，值得提倡。
Objective To explore the effect of acetyl cysteine combined with budesonide atomization in the treatment of elderly patients with COPD based on the anti-aging effect. Methods A total of 60 patients participated in this study. The study started from January 2024 and ended from December 2024. They were divided into two groups, control group and experimental group, with 30 patients in each group. The experimental group was treated with acetylcysteine on the basis of the control group, and the blood oxygen index, inflammatory factors, adverse reactions and quality of life of the two groups were analyzed. Results After the two groups of patients were provided with different intervention measures, the blood oxygen index of the experimental group was better than that of the control group, p<0.05, the level of inflammatory factors of the patients was assessed, the level of inflammatory factors of the experimental group was significantly better, p<0.05, the adverse reactions of the patients were compared, the adverse reactions of the experimental group were lower than that of the control group, p<0.05, the quality of life of the patients was compared. The experimental group was superior to the control group (p<0.05). Conclusion Providing acetyl cysteine and budesonide atomization therapy for elderly COPD patients can improve the blood oxygen index, stabilize the level of inflammatory factors in patients, and reduce the occurrence of adverse reactions, which is worth advocating.
[1] 张红莉,杜明明,赵敏.基于抗衰效应探究乙酰半胱氨酸联合布地奈德雾化治疗老年慢阻肺患者效果[J].中国药物滥用防治杂志,2024,30(8):1487-1490.
[2] 李桂琴.雾化吸入布地奈德联合N-乙酰半胱氨酸泡腾片在慢阻肺患者治疗中的应用效果分析[J].医药前沿,2022, 12(18):49-51.
[3] 张磊.分析布地奈德联合沙丁胺醇及乙酰半胱氨酸雾化吸入治疗慢性阻塞性肺疾病的临床效果[J].系统医学,2022, 7(1):43-47.
[4] 王希杰.布地奈德、特布他林联合乙酰半胱氨酸治疗ICU慢阻肺急性加重期伴呼吸衰竭的疗效分析[J].现代诊断与治疗,2022,33(1):66-68.
[5] 巩欣宇.氨溴索联合乙酰半胱氨酸溶液雾化吸入在慢阻肺急性加重期治疗中的应用[J].中文科技期刊数据库（全文版）医药卫生,2024(11):116-119.
[6] 杨文兴,王叶兰.吸入用乙酰半胱氨酸溶液在老年慢阻肺急性加重期的疗效观察[J].黑龙江中医药,2023,52(6):171-173.
[7] MICHAEL P ,JOSEPH T ,JILL S , et al.HEALTH CARE RESOURCE USE AND COSTS ASSOCIATED WITH PROMPT INITIATION OF BUDESONIDE/ GLYCOPYRROLATE/ FORMOTEROL FUMARATE AMONG PATIENTS WITH COPD: THE EROS STUDY[J]. Chest,2023,164(4S):A4969-A4970.
[8] David S ,Riju R ,Chad M , et al.IMPACT OF UMECLIDINIUM/VILANTEROL (UMEC/VI) VS TIOTROPIUM (TIO), FLUTICASONE PROPIONATE/ SALMETEROL (FP/SAL), AND BUDESONIDE/ FORMOTEROL (B/F) ON TIME-TO-FIRST SEVERE EXACERBATION AMONG PATIENTS WITH COPD WITH HIGH COMORBIDITIES AND HIGH COSTS[J]. Chest,2020,158(4S):A1718-A1719.
[9] Ryun H W ,Ho G L ,Hwan J K , et al.Effects of N-acetylcysteine inhalation therapy on the quality of life of patients with head and neck cancer who are receiving radiation therapy: a prospective non-randomized controlled multi-center study.[J].Journal of cancer research and clinical oncology,2020,147(prepublish):1-9.
[10] Felice V ,Rebecca S B ,Maria M , et al.Activity of N-Acetylcysteine Alone and in Combination with Colistin against Pseudomonas aeruginosa Biofilms and Transcriptomic Response to N-Acetylcysteine Exposure.[J]. Microbiology spectrum,2022,10(4):e0100622-e0100622.